de BoldAJBorensteinHBVeressATSonnenbergH. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci.1981; 28: 89–94.
2.
FlynnGde BoldMLde BoldAJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun1983; 117: 859–65.
3.
CurrieMGGellerDMColeBRPurification and sequence analysis of bioactive atrial peptides (atriopeptins). Science1984; 223: 67–9.
4.
AtlasSAKleinertHDCamargoMJPurification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature1984; 309: 717–26.
5.
KanagawaKMatsuoH. Purification and complete amino acid sequence of alpha human atrial natriuretic polypeptide. Biochem Biophys Res Commun1984; 118: 131–9.
6.
DzauVJBaxterJDCantinMNomenClature for atrial peptides. N Engl J Med.1987; 316: 1278–9.
7.
MiyataAKanagawaKTosimoriTMolecular forms of atrial natriuretic polypeptides circulating in human plasma. Biochem Biophys Res Commun1987; 142: 461–7.
8.
LewickiJAGreenbergBYamanakaMCloning, sequence analysis and processing of the rat and human atrial natriuretic factor precursors. Fed Proc1986; 45: 2086–90.
9.
YandleTGRichardsAMNichollsMGMetabolic clearance rate and plasma half-life of alpha-human atrial natriuretic peptide in man. Life Sci.1986; 38: 1827–33.
10.
SonnenbergJLSakaneYJergAYIdentification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides1988; 9: 173–80.
11.
KatsubeNSchwartzDNeedlemanP. Atriopeptin turnover: Quantitative relationship between in vitro changes in plasma levels and atrial content. J Pharmacol Exp Ther1986; 239: 474–9.
12.
RichardsAMTonoloGMcIntyreGDRadio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens1987; 5: 227–36.
13.
DzauVJRobertsonJISRichardsAMDasRE GainesPooleS. International collaborative study of the proposed international standard for atrial natriuretic factor: An initial analysis of radioimmunoassay results. J Hypertens1987; 5 (Suppl 5): S27–8.
14.
RushkoahoHTothMGantenDThe phorbol ester induced atrial natriuretic peptide secretion is stimulated by forskolin and Bay K8644 and inhibited by 8-bromo-cyclic GMP. Biochem Biophys Res Commun1986; 139: 266–74.
15.
KimuraTAbeKOtaKEffects of acute water load, hypertonic saline infusion and furosemide administration on atrial natriuretic peptide and vasopressin release in humansJ Clin Endocrinol Metab1986; 62: 1003–10.
16.
SagnellaGAMarkanduNDShoreACMacGregorGA. Plasma immunoreactive atrial natriuretic peptide and changes in dietary sodium intake in man. Life Sci.1987; 40: 139–43.
RaineAEGErnePBurgisserEAtrial natriuretic peptide and atrial pressure in patients with congestive cardiac failure. N Engl J Med.1986; 315: 533–7.
19.
WilkinsMRWoodJAAduDChange in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis. Clin Sci.1987; 71: 157–60.
20.
MontorsPTonoloGPoloniaJCorrelates of plasma atrial natriuretic factor in health and hypertension. Hypertension1987; 10: 570–6.
21.
WilkinsMRGammageMDLewisHMEffect of lower body positive pressure on blood pressure, plasma atrial natriuretic factor concentration, sodium and water excretion in healthy volunteers and cardiac transplant recipients. Cardiovasc Res.1988; 22: 231–5.
22.
AndersonJVDonckierJPayneNNAtrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man. Clin Sci.1987; 72: 305–12.
23.
CodyRJAtlasSALaraghJHAtrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal and haemodynamic responses to peptide infusion. J Clin Invest1986; 78: 1362–72.
24.
FujioNOhashiMNawataHAlpha human atrial natriuretic polypeptide reduces the plasma arginine vasopressin concentration in human subjects. Clin Endocrinol1986; 25: 181–7.
UehlingerDEWeidmannPGnadingerMPEffects of human atrial natriuretic peptide on the pressor action of noradrenaline and angiotensin II in normal subjectsJ Hypertens1985; 3 (Suppl. 3): S319–21.
27.
AndersonJVStruthersAChristofidesNICAtrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man. Clin Sci.1986; 70: 507–12.
28.
NapierMAVandlenRLAlberts-SchonbergGSpecific membrane receptors for atrial natriuretic factor in renal and vascular tissues. Proc Natl Acad Sci USA1984; 81: 5946–50.
29.
De LeanAGutkowskaJMcNicollNCharacterisation of specific receptors for atrial natriuretic factor in bovine adrenal zona glomerulosaLife Sci.1984; 35: 2311–18.
30.
KunoTAndresenJWKamisakTCo-purification of an atrial natriuretic factor receptor and particulate guanylate cyclase from rat lung. J Biol Chem.1986; 261: 5817–23.
31.
SchenkDBPhelpsMNPorterJGPurification and subunit composition of atrial natriuretic peptide receptor. Proc Natl Acad Sci USA1987; 84: 1521–5.
32.
PaulAKMaralaRBJaiswalRKSharmaRK. Co-existence of guanylate cyclase and atrial natriuretic factor receptor in a 180-kD protein. Science1987; 235: 1224–6.
33.
TakayanagiRInagamiTSnajdarRMTwo distinct forms of receptors for atrial natriuretic factor in bovine adrenocortical cells. J Biol Chem.1987; 262: 12104–13.
34.
WaldmanSARapoportRMMuradF. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem.1984; 259: 14332–4.
35.
WaldmanSARapoportRMFiscusRRMuradF. Effects of atriopeptin on particulate guanylate cyclase from rat adrenal. Biochim Biophys Acta1985; 845: 298–303.
36.
GerzerRWitzgallHTremblayJRapid increase in plasma and urinary cyclic GMP after bolus injection of atrial natriuretic factor into man. J Clin Endocrinol Metab1985; 61: 1217–9.
37.
HametPTremblayJPangSCCyclic GMP as mediator and biological marker of atrial natriuretic factor. J Hypertens1986; 4 (Suppl 2): S49–56.
38.
WinquistRJFaisonEPWaldmanSAAtrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA1984; 81: 7661–4.
39.
FiscusRRRapoportRMWaldmanSAMuradF. Atriopeptin II elevates cyclic GMP, activates cyclic GMP-dependent protein kinase and causes relaxation in rat thoracic aorta. Biochim Biophys Acta1985; 846: 179–84.
40.
ZcidelMLBrennerBM. Actions of atrial natriuretic peptides on the kidneySemin Nephrol1987; 7: 91–7.
41.
ElliotMEGoodfriendTL. Inhibition of aldosterone synthesis by atrial natriuretic factor. Fed Proc1986; 45: 2376–81.
42.
MaackTSuzukiMAlmeidaFAPhysiological role of silent receptors of atrial natriuretic factor. Science1987; 238: 675–8.
43.
SeidmanCEBlochKDKleinKANucleotide sequences of human and mouse atrial natriuretic factor genes. Science1984; 226: 1206–9.
44.
DayMLSchwartzDWiegandRCVentricular atriopeptin: unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. Hypertension1987; 9: 485–91.
45.
NaruseMObanaKNaruseKAntisera to atrial natriuretic factor reduces urinary sodium excretion and increases plasma renin activity in rats. Biochem Biophys Res Commun1985; 132: 954–60.
46.
SasakiAKidaOKatoJEffects of antiserum against alpha-rat atrial natriuretic peptide in anaesthetised rats. Hypertension1987; 10: 308–12.
47.
HirthCStaschJPJohnAThe renal response to acute hypervolaemia is caused by atrial natriuretic peptides. J Cardiovasc Pharmacol1986; 8: 268–75.
48.
GreenwaldJESakataMMichenerMLIs atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat. J Clin Invest1988; 81: 1036–41.
49.
TunnyTJHigginsBAGordonRD. Plasma levels of atrial natriuretic factor in man in primary aldosteronism, in Gordon's syndrome and Bartter's syndrome. Clin Exp Pharmacol Physiol.1986; 13: 341–5.
50.
GrahamRMBlochKDDelaneyVBBartter's syndrome and the atrial natriuretic factor gene. Hypertension1986; 8: 549–551.